Conversion of abiraterone to D4A drives antitumor activity in prostate cancer

Conversion of abiraterone to D4A drives antitumor activity in prostate cancer

Prostate cancer resistance to castration occurs because tumors acquire the metabolic capability of converting precursor steroids to 5α-dihydrotestosterone (DHT), promoting signaling by the androgen receptor (AR) and the development of castration-resistant prostate cancer (CRPC)1–3. Essential for res...

Full description

Bibliographic Details
Main Authors:	Li, Zhenfei, Bishop, Andrew, Alyamani, Mohammad, Garcia, Jorge A., Dreicer, Robert, Bunch, Dustin, Liu, Jiayan, Upadhyay, Sunil K., Auchus, Richard J., Sharifi, Nima
Format:	Online
Language:	English
Published:	2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506215/

Similar Items

Redirecting abiraterone metabolism to fine tune prostate cancer anti-androgen therapy
by: Li, Zhenfei, et al.
Published: (2016)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
by: Mostaghel, Elahe A
Published: (2014)

Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer
by: Goyal, Jatinder, et al.
Published: (2013)

Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
by: Linden-Castro, Edgar, et al.
Published: (2014)

Abiraterone Acetate
Published: (2012)

Low cost abiraterone
by: Barreiro, Diego Martin, et al.
Published: (2015)

Abiraterone acetate, an inhibitor of adrenal androgen synthesis in “hormone refractory prostate cancer”
by: Goel, Arun Kumar, et al.
Published: (2011)

Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer
by: Harshman, Lauren C., et al.
Published: (2013)

Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
by: Zobniw, Chrystia M, et al.
Published: (2014)

A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone
by: Lin, Jianqing, et al.
Published: (2016)

Abiraterone Acetate Withdrawal Syndrome: Does It Exist?
by: Gauthier, Hélène, et al.
Published: (2012)

Design and Molecular Modeling of Abiraterone-Functionalized Gold Nanoparticles
by: Elżbieta U. Stolarczyk, et al.
Published: (2018-08-01)

Enzymatic and Nonenzymatic Electrochemical Interaction of Abiraterone (Antiprostate Cancer Drug) with Multiwalled Carbon Nanotube Bioelectrodes
by: Aliakbarinodehi, Nima, et al.
Published: (2016)

Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer
by: Tsao, Che-Kai, et al.
Published: (2016)

Screening for functional kinases in metastatic prostate cancer: a glimmer of hope for kinase inhibition
by: Ornstein, Moshe C., et al.
Published: (2016)

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
by: Rehman, Yasser, et al.
Published: (2012)

CYTOCHROME P450 17A1 STRUCTURES WITH PROSTATE CANCER DRUGS ABIRATERONE AND TOK-001
by: DeVore, Natasha M., et al.
Published: (2012)

Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
by: Tolcher, A. W., et al.
Published: (2012)

Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report
by: MARECH, ILARIA, et al.
Published: (2013)

Metastatic Castration-Resistant Prostate Cancer: Two Case Reports of Dramatic Response with Abiraterone Acetate in Patients Heavily Pretreated with Chemotherapy
by: Dupuy, Laura, et al.
Published: (2011)

Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer
by: Omlin, A, et al.
Published: (2013)

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer
by: Pezaro, C, et al.
Published: (2013)

Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions
by: Bedoya, Diego J, et al.
Published: (2013)

Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer
by: Goodman, O B, et al.
Published: (2014)

Comment on ‘Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'
by: Shamash, J, et al.
Published: (2014)

Reply: ‘Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'
by: Omlin, A, et al.
Published: (2014)

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
by: Ferraldeschi, Roberta, et al.
Published: (2015)

Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer
by: Matsubara, Nobuaki, et al.
Published: (2014)

Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy
by: Kim, Ki Bom, et al.
Published: (2015)

Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer
by: Schlack, Katrin, et al.
Published: (2016)

Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer
by: Liu, Chengfei, et al.
Published: (2016)

Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide
by: Benoist, Guillemette E., et al.
Published: (2016)

Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Binder, Moritz, et al.
Published: (2016)

Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation
by: Rauch, Simon, et al.
Published: (2016)

Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer
by: Campora, Sara, et al.
Published: (2016)

Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study
by: Verzoni, Elena, et al.
Published: (2016)

Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate
by: Boegemann, Martin, et al.
Published: (2016)

Neutrophil–lymphocyte ratio is prognostic but not predictive of response to Abiraterone in metastatic castration-resistant prostate cancer
by: Sundar, Santhanam, et al.
Published: (2015)

Effects of Abiraterone Acetate on Chronic Kidney Disease in 2 Patients With Metastatic Castration-resistant Prostate Cancer
by: Francini, Edoardo, et al.
Published: (2014)

Comparisons of Prostate Cancer Inhibitors Abiraterone and TOK-001 Binding with CYP17A1 through Molecular Dynamics
by: Xiao, Fei, et al.
Published: (2015)